Stada plans Spirig generics buyout for $109M; Watson, Novartis in Exelon patent fight;

 @FiercePharma: Are the best times for Big Pharma in China already over? Or will volume make up for new price cuts? Bloomberg: Article | Follow @FiercePharma

> Germany's Stada plans to buy the Swiss drugmaker Spirig Pharma's generics business for about $109 million. Report

> Watson Pharmaceuticals ($WPI) has asked the FDA to approve its version of the Novartis ($NVS) dementia treatment Exelon; the Swiss drugmaker has sued for patent infringement. News

> Watson, meanwhile, has launched its copycat version of Actavis Group's pain treatment Kadian. Story

> Amgen ($AMGN) sold $6 billion in new debt to finance the $5 billion planned stock repurchase announced earlier this week. Item

> Merck's stock gained the most in three months after the company announced its first increase in dividend since 2004. Piece

> India's Aurobindo Pharma hopes its new emphasis on high-value APIs can reverse a downward trend on profits. Report

Biotech News

 @FierceBiotech: We have another new Fierce addition! Please say hello to @MarkHfierce, who will be covering drug delivery, biotech research and more. News | Follow @FierceBiotech

 @JohnCFierce: So Verastem has now raised $68M in VC cash; spent $8.5M and wants a $50M IPO. Sure. Article | Follow @JohnCFierce

 @RyanMFierce: After what's happened at $DNDN, folks will look very carefully at next crop of cancer vax developers like NewLink, which aims for IPO. | Follow @RyanMFierce

 @MaureenFierce: Reading: Resveratrol in humans: Results of a controlled trial. Blog entry | Follow @MaureenFierce

> J&J seeds an ambitious open R&D program for neuroscience. Story

> Lundbeck makes $200M down payment in blockbuster CNS drug pact with Otsuka. Article

And Finally... Health officials worry about illness at Zucotti Park as winter bears down. Report